Cite
HARVARD Citation
Blagden, S. et al. (n.d.). 442TiPA phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignancies. Annals of oncology. p. . [Online].